RxDoctor Payments DataLook up a doctor →

Candie Books

Family · Plymouth, INNPI 1194334631

Payments from drug & device makers

$15,204in general payments, 2019–2025

Across 641 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$2K
  • Novartis$729
  • UCB, Inc.$673
  • Livanova USA, Inc.$659
  • Pfizer$488
  • plus $9K from 52 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie148$2,347
Medtronic22$1,502
Novartis31$729
UCB, Inc.39$673
Livanova USA, Inc.5$659
Pfizer26$488
Otsuka America Pharmaceutical, Inc.12$440
SK Life Science, Inc.20$435
Lundbeck LLC19$426
Biogen23$414
Argenx US, Inc.11$388
MDD US Operations, LLC9$378
Catalyst Pharmaceuticals, Inc.17$375
Vanda Pharmaceuticals Inc.13$366
Teva Pharmaceuticals USA, Inc.22$360
Johnson & Johnson(2 entities)9$303
CSL Behring5$299
Neurocrine Biosciences, Inc.9$292
Banner Life Sciences, LLC8$274
AstraZeneca(2 entities)13$272
Bristol Myers Squibb12$261
Grifols USA, LLC12$235
Genentech USA, Inc.11$231
Mallinckrodt Hospital Products Inc.13$230
EMD Serono, Inc.11$211
TG Therapeutics, Inc.10$202
Amgen9$178
Axsome Therapeutics, Inc.7$172
Neurelis, Inc.6$171
Eisai Inc.4$167
Amneal Pharmaceuticals LLC7$165
Acadia Pharmaceuticals Inc8$141
Takeda Pharmaceuticals U.S.A., Inc.7$132
Jazz Pharmaceuticals Inc.4$113
Octapharma USA, Inc.4$110
Xeris Pharmaceuticals, Inc.5$108
Cycle Pharmaceuticals Inc4$102
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$89
Tanabe Pharma America, Inc.4$77
Aucta Pharmaceuticals, Inc.4$74
Lilly USA, LLC4$72
Alnylam Pharmaceuticals Inc.3$53
Collegium Pharmaceutical, Inc.3$52
Harmony Biosciences LLC3$49
Sumitomo Pharma America, Inc.2$47
Corium, LLC2$44
Scilex Pharmaceuticals Inc.2$42
Cala Health, Inc.2$40
Sanofi2$38
Merz Pharmaceuticals, LLC2$31
Kyowa Kirin, Inc.1$22
Revance Therapeutics, Inc.1$20
Springworks Therapeutics, Inc.1$20
Avanir Pharmaceuticals, Inc.1$19
E.r. Squibb & Sons, L.L.C.1$18
Boston Scientific1$18
Merck1$15
Idorsia Pharmaceuticals US Inc1$14

How this compares

$15,204 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$34,926
Medicare patients
251
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Plymouth

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →